Ms. Lu is experienced in all phases of patent litigation including pre-suit patent analysis, fact and expert discovery, motion practice, summary judgment, bench and jury trials, and post-trial briefing.
Representative matters include:
- Genzyme Corp. v. Dr. Reddy’s Labs., Ltd., No. 13-1506-GMS (D. Del.) – Represented Teva Pharmaceuticals USA, Inc. in patent infringement litigation, including trial, regarding Teva’s application to market a generic version of Genzyme’s stem cell mobilizing agent, Mozobil® (plerixafor).
- Reckitt Benckiser Pharmaceuticals Inc. v. Dr. Reddy’s Laboratories, S.A., No. 14-1451-RGA (D. Del.) – Represented Dr. Reddy’s in patent infringement litigation, including trial, concerning Dr. Reddy’s applications to market generic versions of Suboxone® (buprenorphine hydrochloride and naloxone hydrochloride) sublingual films. After trial, the court found that Dr. Reddy’s proposed generic product did not infringe any of the asserted patents. The case is currently on appeal.
- Indivior Inc. v. Dr. Reddy’s Laboratories, S.A., No. 17-7111 (D. N.J.) – Representing Dr. Reddy’s in patent infringement litigation, including a hearing on motion for a preliminary injunction, concerning Dr. Reddy’s applications to market generic versions of Suboxone® (buprenorphine hydrochloride and naloxone hydrochloride) sublingual films.
- GlaxoSmithKline v. Teva Pharmaceuticals USA, Inc., No. 14-878-LPS (D. Del.) – Represented Teva in patent litigation, including jury trial, concerning Teva’s generic version of Coreg® (carvedilol) tablets. The court granted judgment as a matter of law in favor of Teva. The case is currently on appeal.
- Sophos, Inc. v. RPost Holdings, Inc., No. 13-12856-DJC (D. Mass.) – Represented Sophos in declaratory judgment action regarding Sophos’s network security and email security products. The court granted Sophos’s motion for summary judgment of invalidity on two independent grounds. The case is currently on appeal.
- Genentech, Inc. v. Celltrion, Inc., No. 18-cv-0574 (D. N.J.) – Represented Celltrion and Teva in patent infringement litigation under the BPCIA, including preparations for hearing on motion for a preliminary injunction, concerning Celltrion’s and Teva’s proposed biosimilar rituximab product.
Ms. Lu also commits to pro bono matters including representing unaccompanied minors through the firm’s partnership with Kids in Need of Defense (KIND).
While in law school, Ms. Lu was a student and student director in the Immigration Legal Services Clinic at Yale Law School, and an editor for the Yale Law Journal. She also worked as a summer intern at the Department of Justice Civil Rights Division, Housing and Civil Enforcement Section.
